More On

Pfizer settles Celebrex lawsuit with BYU

The pharmaceutical giant will pay $450 million to end the six-year legal battle

Pfizer Inc. will pay $450 million to settle a six-year lawsuit filed by Brigham Young University (BYU) over the development of the anti-inflammatory drug Celebrex, according to a regulatory filing Tuesday.

The prolonged legal battle centered on a single enzyme, one that was instrumental in the development of anti-arthritis drug Celebrex. BYU’s suit claimed that chemistry professor Daniel Simmons discovered the COX-2 enzyme in the early ‘90s, allowing for the development of “super aspirin,” which would treat inflammation with fewer gastrointestinal side effects.

Alanna Byrne

Bio and more articles

Join the Conversation

Advertisement. Closing in 15 seconds.